Special Issues
December 2016
December 2016
November 2016
October 2016
October 2016
September 2016
August 2016
August 2016
July 2016
June 2016
Volume: 5
Issue: 3
June 2016
May 2016
Volume: 5
Issue: 5
May 2016
Volume: 2
Issue: 2
April 2016
Volume: 5
Issue: 4
April 2016
Volume: 5
Issue: 2
March 2016
Volume: 5
Issue: 3
February 2016
Volume: 5
Issue: 2
February 2016
Volume: 5
Issue: 1
February 2016
Volume: 2
Issue: 1
January 2016
Volume: 5
Issue: 1
Anti-PD-1/PD-L1 Immunotherapy in Lung Cancer: Updates From the ESMO 2016 Congress
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5